Review
. 2018 Jul; 41(1):31-40.
doi: 10.1007/s00281-018-0692-y.

Acquired resistance to cancer immunotherapy

Arianna Draghi 1 Christopher Aled Chamberlain 1 Andrew Furness 2 Marco Donia 3 
Affiliations
  • PMID: 29968044
  •     96 References
  •     9 citations

Abstract

In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

Keywords: Acquired resistance; Cancer immunotherapy; Checkpoint inhibitors; Immune escape; Immune evasion.

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Jonathan M Pitt, Marie Vétizou, +8 authors, Laurence Zitvogel.
Immunity, 2016 Jun 23; 44(6). PMID: 27332730
Highly Cited. Review.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
D H Kaplan, V Shankaran, +4 authors, R D Schreiber.
Proc Natl Acad Sci U S A, 1998 Jun 24; 95(13). PMID: 9636188    Free PMC article.
Highly Cited.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, +25 authors, CheckMate 025 Investigators.
N Engl J Med, 2015 Sep 26; 373(19). PMID: 26406148    Free PMC article.
Highly Cited.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, +23 authors, Katerina Politi.
Cancer Discov, 2017 Oct 14; 7(12). PMID: 29025772    Free PMC article.
Highly Cited.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz, Jonathan J Havel, +22 authors, Timothy A Chan.
Cell, 2017 Oct 17; 171(4). PMID: 29033130    Free PMC article.
Highly Cited.
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
Nisha Nagarsheth, Dongjun Peng, +15 authors, Weiping Zou.
Cancer Res, 2015 Nov 15; 76(2). PMID: 26567139    Free PMC article.
Highly Cited.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Robert Dreicer.
Lancet, 2016 Mar 10; 387(10031). PMID: 26952546    Free PMC article.
Highly Cited.
Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Moshe Sade-Feldman, Yunxin J Jiao, +28 authors, Nir Hacohen.
Nat Commun, 2017 Oct 27; 8(1). PMID: 29070816    Free PMC article.
Highly Cited.
Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.
Karen M Kaluza, Jill M Thompson, +3 authors, Richard G Vile.
Int J Cancer, 2011 Sep 22; 131(4). PMID: 21935923    Free PMC article.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Paul F Robbins, Richard A Morgan, +18 authors, Steven A Rosenberg.
J Clin Oncol, 2011 Feb 02; 29(7). PMID: 21282551    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Evan W Alley, Juanita Lopez, +4 authors, Emilie van Brummelen.
Lancet Oncol, 2017 Mar 16; 18(5). PMID: 28291584
Highly Cited.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, +16 authors, Stephan A Grupp.
N Engl J Med, 2014 Oct 16; 371(16). PMID: 25317870    Free PMC article.
Highly Cited.
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.
Eleanor N Fish, Leonidas C Platanias.
Mol Cancer Res, 2014 Sep 14; 12(12). PMID: 25217450    Free PMC article.
Review.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Padmanee Sharma, Margitta Retz, +16 authors, Matthew D Galsky.
Lancet Oncol, 2017 Jan 31; 18(3). PMID: 28131785
Highly Cited.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Kevin J Harrington, Robert L Ferris, +21 authors, Joël Guigay.
Lancet Oncol, 2017 Jun 28; 18(8). PMID: 28651929    Free PMC article.
Highly Cited.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
Jennifer Landsberg, Judith Kohlmeyer, +8 authors, Thomas Tüting.
Nature, 2012 Oct 12; 490(7420). PMID: 23051752
Highly Cited.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Jacob Schachter, Antoni Ribas, +17 authors, Caroline Robert.
Lancet, 2017 Aug 22; 390(10105). PMID: 28822576
Highly Cited.
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Jake S O'Donnell, Mark J Smyth, Michele W L Teng.
Genome Med, 2016 Oct 27; 8(1). PMID: 27782862    Free PMC article.
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.
Gavin P Dunn, Kathleen C F Sheehan, Lloyd J Old, Robert D Schreiber.
Cancer Res, 2005 Apr 19; 65(8). PMID: 15833880
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nicholas P Restifo, Mark E Dudley, Steven A Rosenberg.
Nat Rev Immunol, 2012 Mar 23; 12(4). PMID: 22437939    Free PMC article.
Highly Cited. Review.
T-cell receptor gene therapy--ready to go viral?
Terhi Karpanen, Johanna Olweus.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548533    Free PMC article.
Review.
Epigenetic modulation in cancer immunotherapy.
Stuart J Gallagher, Elena Shklovskaya, Peter Hersey.
Curr Opin Pharmacol, 2017 Jun 14; 35. PMID: 28609681
Review.
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, +2 authors, Nir Hacohen.
Cell, 2015 Jan 17; 160(1-2). PMID: 25594174    Free PMC article.
Highly Cited.
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.
Gulidanna Shayan, Raghvendra Srivastava, +3 authors, Robert L Ferris.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197389    Free PMC article.
Highly Cited.
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Ahmad A Tarhini, Howard Edington, +9 authors, John M Kirkwood.
PLoS One, 2014 Feb 06; 9(2). PMID: 24498358    Free PMC article.
Highly Cited.
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Jeffrey P Ward, Matthew M Gubin, Robert D Schreiber.
Adv Immunol, 2016 Mar 01; 130. PMID: 26922999    Free PMC article.
Highly Cited. Review.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
De-novo and acquired resistance to immune checkpoint targeting.
Nicholas L Syn, Michele W L Teng, Tony S K Mok, Ross A Soo.
Lancet Oncol, 2017 Dec 07; 18(12). PMID: 29208439
Highly Cited. Review.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, +47 authors, Özlem Türeci.
Nature, 2017 Jul 06; 547(7662). PMID: 28678784
Highly Cited.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Howard L Kaufman, Jeffery Russell, +15 authors, Paul Nghiem.
Lancet Oncol, 2016 Sep 07; 17(10). PMID: 27592805    Free PMC article.
Highly Cited.
Adaptive Immune Resistance: How Cancer Protects from Immune Attack.
Antoni Ribas.
Cancer Discov, 2015 Aug 15; 5(9). PMID: 26272491    Free PMC article.
Highly Cited. Review.
Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors.
Shuanglin Han, Olivier Latchoumanin, +4 authors, Liang Qiao.
Cancer Lett, 2017 Jan 17; 390. PMID: 28089834
Review.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
Eric Tran, Paul F Robbins, +9 authors, Steven A Rosenberg.
N Engl J Med, 2016 Dec 14; 375(23). PMID: 27959684    Free PMC article.
Highly Cited.
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.
M H Geukes Foppen, M Donia, I M Svane, J B A G Haanen.
Mol Oncol, 2015 Nov 19; 9(10). PMID: 26578452    Free PMC article.
Review.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin, Jesse M Zaretsky, +24 authors, Antoni Ribas.
Cancer Discov, 2016 Dec 03; 7(2). PMID: 27903500    Free PMC article.
Highly Cited.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Jianjun Gao, John F Ward, +16 authors, Padmanee Sharma.
Nat Med, 2017 Mar 28; 23(5). PMID: 28346412    Free PMC article.
Highly Cited.
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Kellie N Smith, +26 authors, Victor E Velculescu.
Cancer Discov, 2016 Dec 30; 7(3). PMID: 28031159    Free PMC article.
Highly Cited.
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
M F Krummel, J P Allison.
J Exp Med, 1995 Aug 01; 182(2). PMID: 7543139    Free PMC article.
Highly Cited.
Mechanisms of resistance to immune checkpoint inhibitors.
Russell W Jenkins, David A Barbie, Keith T Flaherty.
Br J Cancer, 2018 Jan 11; 118(1). PMID: 29319049    Free PMC article.
Highly Cited. Review.
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert Chen, Pier Luigi Zinzani, +15 authors, KEYNOTE-087.
J Clin Oncol, 2017 Apr 26; 35(19). PMID: 28441111    Free PMC article.
Highly Cited.
Immunoediting of cancers may lead to epithelial to mesenchymal transition.
Keith L Knutson, Hailing Lu, +6 authors, Mary L Disis.
J Immunol, 2006 Jul 20; 177(3). PMID: 16849459
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Joseph L Benci, Bihui Xu, +16 authors, Andy J Minn.
Cell, 2016 Dec 03; 167(6). PMID: 27912061    Free PMC article.
Highly Cited.
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Marco Donia, Katja Harbst, +20 authors, Inge Marie Svane.
Cancer Res, 2017 Jun 29; 77(17). PMID: 28655789
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Paul T Nghiem, Shailender Bhatia, +28 authors, Martin A Cheever.
N Engl J Med, 2016 Apr 20; 374(26). PMID: 27093365    Free PMC article.
Highly Cited.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Antoni Ribas, Omid Hamid, +25 authors, Caroline Robert.
JAMA, 2016 Apr 20; 315(15). PMID: 27092830
Highly Cited.
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Tanguy Y Seiwert, Barbara Burtness, +9 authors, Laura Q Chow.
Lancet Oncol, 2016 Jun 02; 17(7). PMID: 27247226
Highly Cited.
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Scott D Brown, Rene L Warren, +4 authors, Robert A Holt.
Genome Res, 2014 May 02; 24(5). PMID: 24782321    Free PMC article.
Highly Cited.
Paradoxical effects of interleukin-10 on the maturation of murine myeloid dendritic cells.
Dianne L Commeren, Peter L Van Soest, +3 authors, Eric Braakman.
Immunology, 2003 Sep 27; 110(2). PMID: 14511232    Free PMC article.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Antje Sucker, Fang Zhao, +20 authors, Annette Paschen.
Nat Commun, 2017 Jun 01; 8. PMID: 28561041    Free PMC article.
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Erin E Burke, Jonathan S Zager.
Expert Opin Drug Metab Toxicol, 2018 Mar 21; 14(4). PMID: 29557682
Review.
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Florie Bertrand, Anne Montfort, +9 authors, Bruno Ségui.
Nat Commun, 2017 Dec 24; 8(1). PMID: 29273790    Free PMC article.
Highly Cited.
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.
S A Quezada, K S Peggs.
Br J Cancer, 2013 Mar 21; 108(8). PMID: 23511566    Free PMC article.
Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber.
Science, 2015 Apr 04; 348(6230). PMID: 25838375
Highly Cited. Review.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Antoni Ribas, Reinhard Dummer, +17 authors, Georgina V Long.
Cell, 2017 Sep 09; 170(6). PMID: 28886381    Free PMC article.
Highly Cited.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, +18 authors, Dario A A Vignali.
Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141    Free PMC article.
Highly Cited.
Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.
Patrick A Ott, Zhuting Hu, +37 authors, Catherine J Wu.
Nature, 2018 Mar 16; 555(7696). PMID: 29542692    Free PMC article.
Neoantigen landscape dynamics during human melanoma-T cell interactions.
Els M E Verdegaal, Noel F C C de Miranda, +11 authors, Sjoerd H van der Burg.
Nature, 2016 Jun 29; 536(7614). PMID: 27350335
Highly Cited.
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Thomas Powles, Peter H O'Donnell, +16 authors, Noah M Hahn.
JAMA Oncol, 2017 Aug 18; 3(9). PMID: 28817753    Free PMC article.
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
Sean P Arlauckas, Christopher S Garris, +9 authors, Mikael J Pittet.
Sci Transl Med, 2017 May 12; 9(389). PMID: 28490665    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, +23 authors, Peter S Hammerman.
Nat Commun, 2016 Feb 18; 7. PMID: 26883990    Free PMC article.
Highly Cited.
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Hyun-Bae Jie, Patrick J Schuler, +5 authors, Robert L Ferris.
Cancer Res, 2015 Apr 03; 75(11). PMID: 25832655    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Tumor-associated macrophages in cancers.
W Hu, X Li, +3 authors, C Wu.
Clin Transl Oncol, 2015 Aug 13; 18(3). PMID: 26264497
Review.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chien-Chung Chang, Giuseppe Pirozzi, +6 authors, Soldano Ferrone.
J Biol Chem, 2015 Sep 19; 290(44). PMID: 26381407    Free PMC article.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, +3 authors, Ana C Anderson.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927    Free PMC article.
Highly Cited.
The IFN gamma receptor: a paradigm for cytokine receptor signaling.
E A Bach, M Aguet, R D Schreiber.
Annu Rev Immunol, 1997 Jan 01; 15. PMID: 9143700
Highly Cited. Review.
Resistance to PD1/PDL1 checkpoint inhibition.
Jake S O'Donnell, Georgina V Long, +2 authors, Mark J Smyth.
Cancer Treat Rev, 2016 Dec 13; 52. PMID: 27951441
Highly Cited. Review.
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Joshua Bauml, Tanguy Y Seiwert, +15 authors, Robert Haddad.
J Clin Oncol, 2017 Mar 23; 35(14). PMID: 28328302    Free PMC article.
Highly Cited.
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.
Marta Santisteban, Jennifer M Reiman, +10 authors, Keith L Knutson.
Cancer Res, 2009 Mar 12; 69(7). PMID: 19276366    Free PMC article.
Highly Cited.
Acquired resistance to immunotherapy and future challenges.
Nicholas P Restifo, Mark J Smyth, Alexandra Snyder.
Nat Rev Cancer, 2016 Jan 30; 16(2). PMID: 26822578    Free PMC article.
Highly Cited.
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, +8 authors, Craig H Moskowitz.
J Clin Oncol, 2016 Jun 30; 34(31). PMID: 27354476    Free PMC article.
Highly Cited.
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Jianjun Gao, Lewis Zhichang Shi, +13 authors, Padmanee Sharma.
Cell, 2016 Sep 27; 167(2). PMID: 27667683    Free PMC article.
Highly Cited.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, +26 authors, Antoni Ribas.
N Engl J Med, 2016 Jul 20; 375(9). PMID: 27433843    Free PMC article.
Highly Cited.
Regulatory T cells: a potential target in cancer immunotherapy.
Kohei Shitara, Hiroyoshi Nishikawa.
Ann N Y Acad Sci, 2018 Mar 23; 1417(1). PMID: 29566262
Highly Cited. Review.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, +16 authors, Philippe Armand.
N Engl J Med, 2014 Dec 09; 372(4). PMID: 25482239    Free PMC article.
Highly Cited.
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
Ruea-Yea Huang, Ariel Francois, +2 authors, Kunle Odunsi.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197366    Free PMC article.
Highly Cited.
The future of immune checkpoint therapy.
Padmanee Sharma, James P Allison.
Science, 2015 Apr 04; 348(6230). PMID: 25838373
Highly Cited. Review.
Current Perspectives in Cancer Immunotherapy.
Theodoulakis Christofi, Stavroula Baritaki, +2 authors, Apostolos Zaravinos.
Cancers (Basel), 2019 Oct 03; 11(10). PMID: 31575023    Free PMC article.
Review.
Anti-cancer immunotherapy: breakthroughs and future strategies.
Mads Hald Andersen.
Semin Immunopathol, 2018 Sep 23; 41(1). PMID: 30242450
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Morgane Denis, Michael Duruisseaux, Marie Brevet, Charles Dumontet.
Front Immunol, 2020 Apr 09; 11. PMID: 32265935    Free PMC article.
Review.
VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
Mohamed A ElTanbouly, Walburga Croteau, Randolph J Noelle, J Louise Lines.
Semin Immunol, 2019 Oct 13; 42. PMID: 31604531    Free PMC article.
Review.
Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.
Claudia Wickenhauser, Daniel Bethmann, +6 authors, Barbara Seliger.
Cancers (Basel), 2021 Feb 10; 13(4). PMID: 33557271    Free PMC article.
Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics.
Ajita Jindal, Sounik Sarkar, Aftab Alam.
Front Chem, 2021 Mar 13; 9. PMID: 33708759    Free PMC article.
Review.
Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles.
Alena Liskova, Marek Samec, +16 authors, Peter Kubatka.
EPMA J, 2021 May 25; 12(2). PMID: 34025826    Free PMC article.
Review.
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update.
Sonja Vukadin, Farah Khaznadar, +2 authors, Martina Smolic.
Biomedicines, 2021 Aug 07; 9(7). PMID: 34356899    Free PMC article.
Review.
The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.
Xin Xie, Jingwen Lv, +7 authors, Xiaopeng Li.
Transl Oncol, 2021 Nov 23; 15(1). PMID: 34808461    Free PMC article.